Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease ...
Ainos, Inc. (NASDAQ: AIMD) is a healthcare technology company headquartered in Houston, Texas, with operations in San Diego, California, and Taiwan. Founded in 1984 as Amarillo Biosciences, Inc., the company rebranded to Ainos in May 2021 to reflect its dual-platform focus on AI-driven 'smelltech' and immune therapeutics. Business Segments: The ...Ainos, Inc. (NASDAQ: AIMD) is a healthcare technology company headquartered in Houston, Texas, with operations in San Diego, California, and Taiwan. Founded in 1984 as Amarillo Biosciences, Inc., the company rebranded to Ainos in May 2021 to reflect its dual-platform focus on AI-driven 'smelltech' and immune therapeutics.
Business Segments: The company operates two primary platforms:
1. **AI Nose Platform**: This proprietary technology digitizes scent into a 'Smell ID' using a Smell Language Model (SLM). The AI Nose module, touted as the world's first commercial product of its kind, targets applications in robotics, smart factories, environmental monitoring, and medical diagnostics. It holds 50+ patents and is positioned to create a smell intelligence network.
2. **VELDONA® (Very Low-Dose Oral Interferon Alpha)**: This oral formulation leverages the therapeutic properties of interferon-alpha for human and animal diseases, with ongoing clinical development. The company is also advancing a point-of-care diagnostics portfolio, including a COVID-19 antigen rapid test and a nucleic acid test, integrated with the Ainos App for personal and enterprise management.
Financial and Operational Overview: As of the latest TTM data, Ainos has a market cap of approximately $10.97 million, with a stock price of $1.49. The company faces financial challenges, with negative net margins (-1062.8%), negative working capital (-$14.09 million), and a debt-to-equity ratio of 4.21. Employee count stands at 41, classified as a micro-cap entity. Key financial ratios indicate heavy R&D spending (475% of revenue) and SG&A expenses (187% of revenue), reflecting an early-stage, growth-oriented cost structure.
Leadership and Key People: The CEO, President, and Chairman is Chun-Hsien Tsai, who has served since April 2021. CFO Hsin-Liang Lee and Director of Corporate Development Chih-Heng Lu are part of the executive team.
Corporate History and Vision: The company's vision is to digitize scent and bridge the gap between smell and technology, aiming to build a comprehensive smell intelligence network. Despite financial losses, Ainos continues to invest heavily in R&D and patent expansion, targeting future commercialization of its AI Nose technology and VELDONA platform. The company is listed on the NASDAQ Capital Market and is an active player in the biotechnology sector.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$124157
+499.0%
-5.6%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-14.8M
+0.6%
-86.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-3767.2%
-2350.6%
-7.0%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-11268.3%
+83.1%
-104.0%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-11897.0%
+83.4%
-97.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.6M
+20.2%
-46.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-3744.7%
+86.7%
-55.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
145.5%
+88.1%
+73.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.06x
-3.7%
-75.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
